Canandaigua National Trust Co of Florida Purchases New Shares in Pfizer Inc. $PFE

Canandaigua National Trust Co of Florida acquired a new position in shares of Pfizer Inc. (NYSE:PFE) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 42,478 shares of the biopharmaceutical company’s stock, valued at approximately $1,211,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Keb Asset Management LLC purchased a new stake in shares of Pfizer in the second quarter valued at $26,000. Field & Main Bank purchased a new stake in Pfizer during the 2nd quarter worth about $27,000. Evolution Wealth Management Inc. raised its stake in Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 566 shares during the last quarter. Bullseye Investment Management LLC purchased a new position in Pfizer in the 2nd quarter valued at about $28,000. Finally, Timbuktu Capital Management LLC purchased a new position in Pfizer in the 2nd quarter valued at about $29,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on PFE. Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Sunday, September 13th. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. HSBC increased their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday, September 10th. Scotiabank increased their price target on shares of Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a research note on Tuesday. Finally, Guggenheim decreased their price target on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a report on Friday, August 7th. Five research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $28.56.

Pfizer Trading Up 1.7%

Shares of NYSE PFE traded up $0.46 during midday trading on Wednesday, hitting $27.96. The stock had a trading volume of 31,210,171 shares, compared to its average volume of 40,538,586. The company has a market capitalization of $159.39 billion, a price-to-earnings ratio of 36.80, a PEG ratio of 1.84 and a beta of 0.32. Pfizer Inc. has a 1-year low of $23.62 and a 1-year high of $29.21. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The company has a fifty day moving average price of $27.50 and a 200 day moving average price of $26.48.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the company earned $0.78 EPS. The company’s revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts predict that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 annualized dividend and a dividend yield of 6.2%. Pfizer’s dividend payout ratio is presently 226.32%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved Pfizer’s TUKYSA (tucatinib) regimen with trastuzumab and pertuzumab as a front-line maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer. Expanding TUKYSA into an earlier treatment setting could increase its addressable market and support oncology revenue growth. Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer
• Positive Sentiment: Pfizer reported positive Phase 3 results for oral LITFULO in nonsegmental vitiligo, including meaningful facial and total-body repigmentation with a favorable safety profile. Planned regulatory submissions could broaden the drug’s use and strengthen Pfizer’s immunology pipeline. Pfizer Posted Positive Phase 3 Vitiligo Results For LITFULO
• Positive Sentiment: Pfizer declared its quarterly dividend at $0.43 per share, maintaining an annualized payout of $1.72 and a yield above 6% based on recent trading levels. The sizable income return may attract value and income-oriented investors. Pfizer Declares Fourth-Quarter 2026 Dividend
• Neutral Sentiment: Pfizer will eliminate approximately 330 jobs at its Sicily, Italy, plant. The cuts may reduce costs and align capacity with demand, but they also underscore ongoing restructuring and operational pressure. Pfizer to cut around 330 jobs in Italy
• Negative Sentiment: Vaxcyte’s VAX-31 vaccine produced competitive Phase 3 results against Pfizer’s Prevnar 20. A credible challenger could pressure Pfizer’s $6.49 billion Prevnar franchise through future pricing, market-share and revenue risks. Pfizer’s Prevnar Franchise Faces a New Challenger
• Negative Sentiment: Several valuation analyses highlight that Pfizer’s dividend payout has exceeded reported earnings, raising questions about long-term dividend sustainability despite the stock’s low valuation and high yield. This may limit upside for investors focused on earnings quality and balance-sheet strength. Is Pfizer a Good or Bad Investment at Today’s Price?

Pfizer Profile

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.